David Sinclair: The GLP-1 Side Effect No One Talks About, What AI Found in His Lab, and Reversing Blindness | Q&A EP #251

April 28, 2026

AI Summary

5 min read

In a lively Q&A session at a Moonshots event, biologist David Sinclair fields questions on longevity science, blending his lab's latest findings with practical advice on lifestyle, mindset, and emerging therapies. Drawing from his research on reversing aging via epigenetic reprogramming (like OSK genes delivered by ER100 therapy), he emphasizes actionable steps while acknowledging genetics' role and the power of belief.

GLP-1 Drugs: Benefits, Dosing, and a Rare Risk

Sinclair highlights growing evidence that GLP-1 agonists (like those for weight loss) benefit the heart and brain beyond shedding pounds, paving the way for broader longevity medicines. Weight loss itself accelerates anti-aging by countering obesity's toll on lifespan. For those not needing major weight reduction, he suggests doctor-supervised microdosing to tap these effects safely.

A key caveat: these drugs carry a rare risk of non-arteritic anterior ischemic optic neuropathy (NAION), causing sudden blindness in about 20,000-30,000 US cases yearly. NAION can occur congenitally or from other causes, but Sinclair's lab plans ER100 trials to test reversal. All use must involve medical oversight, as self-administration is unwise.

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

What you'll learn

1 (00:00) **GLP-1 Benefits and Risks** - Sinclair highlights heart/brain gains from GLP-1s but warns of rare blindness side effect (NAION)
2 (00:12) **AI Accelerating Aging Research** - Lab uses AI for drug design, scanning billions of molecules to reverse aging
3 (00:33) **Overcoming Genetic Destiny** - Personal family history shows lifestyle beats genes; mindset most powerful
4 (01:06) **Sleep and Exercise Priorities** - Sinclair sacrifices for mission but emphasizes movement via treadmill desk
5 (02:07) **Hayflick Limit and Telomeres** - OSK activates telomerase to extend cell divisions; combinable with other therapies
6 (03:09) **GLP-1 for Longevity Protocols** - Weight loss biggest aging accelerator reversed; paves way for future drugs
7 (05:06) **Xenohormesis: Eat Stressed Plants** - Polyphenols signal adversity, activating sirtuins like resveratrol/quercetin

+ Full timestamped outline available in the app

Show Notes

This episode was filmed at the 2026 Abundance360 Summit. Learn more at https://www.abundance360.com/

This Q&A is about longevity, and especially how David Sinclair sees AI speeding up drug discovery, biological-age reversal, and the future of healthspan. It also covers GLP-1s, telomeres, genetics, muscle preservation, hormone replacement, indoor environment, and the role of mindset in aging well.

Get access to metatrends 10+ years before anyone else - https://qr.diamandis.com/metatrends

Peter H. Diamandis, MD, is the Founder of XPRIZE, Singularity University, ZeroG, and A360

David A. Sinclair, A.O., Ph.D., is a tenured Professor of Genetics at Harvard Medical School and a serial biotech entrepreneur. Peter H. Diamandis, MD, is the Founder of XPRIZE, Singularity University, ZeroG, and A360

–

My companies:

Apply to Dave's and my new fund:https://qr.diamandis.com/linkventureslanding

Go to Blitzy to book a free demo and start building today: https://qr.diamandis.com/blitzy

Your body is incredibly good at hiding disease. Schedule a call with Fountain Life to add healthy decades to your life, and to learn more about their Memberships: https://www.fountainlife.com/peter

Connect with Peter:

Connect with David

Listen to MOONSHOTS:

–

*Recorded on March 9th, 2026

*The views expressed by me and all guests are personal opinions and do not constitute Financial, Medical, or Legal advice.

Learn more about your ad choices. Visit megaphone.fm/adchoices